SEC Form 4 · accession 0001179110-19-002283
Strongbridge Biopharma plc · SBBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Pauls
Officer — President & CEO · Director
Period of report
Feb 20, 2019
Accepted (ET)
Feb 22, 2019 · 8:50 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001634432
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 20, 2019 | A | 50,000 | $0.00 | A | 72,608 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $4.67 | Feb 20, 2019 | A | 400,000 | A | — | Feb 20, 2029 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date.